Analysts forecast that aTyr Pharma Inc (NASDAQ:LIFE) will post earnings per share (EPS) of ($0.21) for the current quarter, Zacks reports. Zero analysts have made estimates for aTyr Pharma’s earnings. aTyr Pharma posted earnings per share of ($0.36) during the same quarter last year, which would indicate a positive year over year growth rate of 41.7%. The company is scheduled to announce its next quarterly earnings report on Monday, May 13th.
On average, analysts expect that aTyr Pharma will report full-year earnings of ($0.80) per share for the current financial year. For the next financial year, analysts forecast that the business will report earnings of ($0.99) per share. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow aTyr Pharma.
aTyr Pharma (NASDAQ:LIFE) last issued its quarterly earnings data on Monday, March 25th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.01.
LIFE traded up $0.02 during trading on Friday, reaching $0.56. The stock had a trading volume of 1,100 shares, compared to its average volume of 807,879. aTyr Pharma has a one year low of $0.38 and a one year high of $2.65. The stock has a market cap of $20.73 million, a PE ratio of -0.49 and a beta of 2.45. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.25.
An institutional investor recently raised its position in aTyr Pharma stock. Renaissance Technologies LLC grew its stake in aTyr Pharma Inc (NASDAQ:LIFE) by 107.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,107,025 shares of the biotechnology company’s stock after acquiring an additional 573,164 shares during the period. Renaissance Technologies LLC owned 3.71% of aTyr Pharma worth $899,000 at the end of the most recent reporting period. 30.47% of the stock is owned by institutional investors.
aTyr Pharma Company Profile
aTyr Pharma, Inc, a clinical stage biotechnology company, engages in the discovery and development of medicines for the treatment of cancer and lung disease in the United States. The company's therapeutic candidate pipeline that includes ATYR1923 candidate, an agonist of the Resokine pathway that is in Phase I clinical trial designed to temper immune engagement in interstitial lung diseases; and ORCA program, a preclinical research stage program that targets immuno-oncology pathway using antibodies to enhance the immune response in tumor settings.
See Also: Terms to Better Understand Call Options
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.